Matching-adjusted indirect treatment comparison of [177Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [177Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours
Head-to-head comparisons of the efficacy of treatments for gastroenteropancreatic neuroendocrine tumours (GEP-NETs) have not yet been reported. This study used a series of matching-adjusted indirect comparisons to indirectly compare the effectiveness of [177Lu]Lu-DOTA-TATE to everolimus, sunitinib a...
Guardado en:
Autores principales: | Mohid S. Khan, Elaine Stamp, Cormac Sammon, Tessa Brabander, Wouter W. de Herder, Marianne E. Pavel |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d4894036001b4790bd19ca639cc337bc |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Use of [177Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study
por: Matthew Glover, et al.
Publicado: (2021) -
Can the peptide receptor radionuclide therapy [177Lu]Lu-DOTA-TATE provide a net benefit for NET patients?
por: Martyn E. Caplin
Publicado: (2021) -
Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
por: Peter Frøhlich Staanum, et al.
Publicado: (2021) -
Isotope separation of 176Lu a precursor to 177Lu medical isotope using broadband lasers
por: M. V. Suryanarayana
Publicado: (2021) -
p53-Mediated Radiosensitization of <sup>177</sup>Lu-DOTATATE in Neuroblastoma Tumor Spheroids
por: Sara Lundsten, et al.
Publicado: (2021)